Search Results | Cancer Research | American Association for Cancer Research

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Abstract 3109: ALK as a valid therapeutic target for the treatment of rhabdomyosarcoma

Monika Wierdl, Lyudmila Tsurkan, Viktor Tollemar, Lying Chi, Elizabeth Stewart, Michael A. Dyer, Philip M. Potter

Cancer Res (2014) 74 (19_Supplement): 3109.

DOI: https://doi.org/10.1158/1538-7445.AM2014-3109

Published: 01 October 2014

View article

Journal Articles

Abstract #2897: Contribution of human liver carboxylesterase and human intestinal carboxylesterase to the activation of Irinotecan (CPT-11)

Michael Hatfield, Lyudmila Tsurkan, Latorya Hicks, Janice Hyatt, Carol Edwards, Monika Wierdl, Philip Potter

Cancer Res (2009) 69 (9_Supplement): 2897.

Published: 01 May 2009

View article

Journal Articles

Use of carboxylesterase inhibitors and anti-hiCE specific antibodies to evaluate CPT-11 activation

Michael Hatfield, Latorya Hicks, Janice Hyatt, Lyudmila Tsurkan, Monika Wierdl, Carol Edwards, Philip Potter

Cancer Res (2008) 68 (9_Supplement): 4767.

Published: 01 May 2008

View article

Journal Articles

Tumor-Targeted Enzyme/Prodrug Therapy Mediates Long-term Disease-Free Survival of Mice Bearing Disseminated Neuroblastoma

Mary K. Danks, K. Jin Yoon, Rebecca A. Bush, Joanna S. Remack, Monika Wierdl, Lyudmila Tsurkan, Seung U. Kim, Elizabeth Garcia, Marianne Z. Metz, Joseph Najbauer, Philip M. Potter, Karen S. Aboody

Cancer Res (2007) 67 (1): 22–25.

DOI: https://doi.org/10.1158/0008-5472.CAN-06-3607

Published: 08 January 2007

View article

Journal Articles

Analysis of the human intestinal carboxylesterase and development of specific inhibitors to ameliorate the delayed diarrhea associated with CPT-ll administration.

Michael J. Hatfield, Lyudmila Tsurkan, Janice L. Hyatt, Carol C. Edwards, Monika Wierdl, Philip M. Potter

Cancer Res (2006) 66 (8_Supplement): 1299.

Published: 15 April 2006

View article

Journal Articles

Human neural progenitor cells (NPCs) as delivery vectors for therapeutic transgenes: NPC-directed enzyme prodrug therapy (NDEPT)

Karen S. Aboody, Rebecca A. Bush, Elizabeth Garcia, Marianne Metz, Doris A. Phelps, Joanna Remack, Monika Wierdl, K. Jin Yoon, Philip M. Potter, Mary K. Danks

Cancer Res (2005) 65 (9_Supplement): 796.

Published: 01 May 2005

View article

Journal Articles

VDEPT using a rabbit liver carboxylesterase and CPT-11.

Christopher L. Morton, Monika Wierdl, Peter J. Houghton, Mary K. Danks, Philip M. Potter

Cancer Res (2004) 64 (7_Supplement): 871.

Published: 01 April 2004

View article

Journal Articles

A Virus-directed Enzyme Prodrug Therapy Approach to Purging Neuroblastoma Cells from Hematopoietic Cells Using Adenovirus Encoding Rabbit Carboxylesterase and CPT-11

Mandy M. Meck, Monika Wierdl, Lars M. Wagner, Rebecca A. Burger, Sylvie M. Guichard, Erik. J. Krull, Linda C. Harris, Philip M. Potter, Mary K. Danks

Cancer Res (2001) 61 (13): 5083–5089.

Published: 01 July 2001

View article

Journal Articles

Sensitization of Human Tumor Cells to CPT-11 via Adenoviral-mediated Delivery of a Rabbit Liver Carboxylesterase

Monika Wierdl, Christopher L. Morton, James K. Weeks, Mary K. Danks, Linda C. Harris, Philip M. Potter

Cancer Res (2001) 61 (13): 5078–5082.

Published: 01 July 2001

View article

Journal Articles

Activation of CPT-11 in Mice: Identification and Analysis of a Highly Effective Plasma Esterase

Christopher L. Morton, Monika Wierdl, LaGora Oliver, Margaret K. Ma, Mary K. Danks, Clinton F. Stewart, Julie L. Eiseman, Philip M. Potter

Cancer Res (2000) 60 (15): 4206–4210.

Published: 01 August 2000

View article

Journal Articles

Cellular Localization Domains of a Rabbit and a Human Carboxylesterase: Influence on Irinotecan (CPT-11) Metabolism by the Rabbit Enzyme

Philip M. Potter, Judith S. Wolverton, Christopher L. Morton, Monika Wierdl, Mary K. Danks

Cancer Res (1998) 58 (16): 3627–3632.

Published: 01 August 1998

View article

NARROW

Abstract 3109: ALK as a valid therapeutic target for the treatment of rhabdomyosarcoma

Abstract #2897: Contribution of human liver carboxylesterase and human intestinal carboxylesterase to the activation of Irinotecan (CPT-11)

Use of carboxylesterase inhibitors and anti-hiCE specific antibodies to evaluate CPT-11 activation

Tumor-Targeted Enzyme/Prodrug Therapy Mediates Long-term Disease-Free Survival of Mice Bearing Disseminated Neuroblastoma

Analysis of the human intestinal carboxylesterase and development of specific inhibitors to ameliorate the delayed diarrhea associated with CPT-ll administration.

Human neural progenitor cells (NPCs) as delivery vectors for therapeutic transgenes: NPC-directed enzyme prodrug therapy (NDEPT)

VDEPT using a rabbit liver carboxylesterase and CPT-11.

A Virus-directed Enzyme Prodrug Therapy Approach to Purging Neuroblastoma Cells from Hematopoietic Cells Using Adenovirus Encoding Rabbit Carboxylesterase and CPT-11

Sensitization of Human Tumor Cells to CPT-11 via Adenoviral-mediated Delivery of a Rabbit Liver Carboxylesterase

Activation of CPT-11 in Mice: Identification and Analysis of a Highly Effective Plasma Esterase

Cellular Localization Domains of a Rabbit and a Human Carboxylesterase: Influence on Irinotecan (CPT-11) Metabolism by the Rabbit Enzyme

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only